Tuberculosis (TB) and human immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS) constitute the main burden of infectious disease in resource-limited …

Background The results of some reports have suggested that treatment of isoniazid-resistant
tuberculosis with the recommended regimens of first-line drugs might be suboptimal. We …

In order to support countries in their effort to respond to the challenges posed by the TB
epidemic over the years, WHO has produced and regularly updated guidelines for the …

Between 2011 and 2019, WHO has developed and issued evidence-based policy
recommendations on the treatment and care of patients with DR-TB. These policy …

Human immunodeficiency virus (HIV) associated tuberculosis (TB) remains a major global
public health challenge, with an estimated 1.4 million patients worldwide. Co-infection with …

The drug isoniazid (INH) is a key component of global tuberculosis (TB) control
programmes. It is estimated, however, that 16.1% of TB disease cases in the former Soviet …

Background Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most
common form of drug resistance, and is associated with failure, relapse, and acquired …

Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although
the drug regimens used to treat tuberculosis in these patients are the same as those used in …

The human immunodeficiency virus (HIV) epidemic has led to an increase in the incidence
of tuberculosis globally, particularly in sub-Saharan Africa. Coinfection with HIV leads to …

Currently, the standard short-course chemotherapy for tuberculosis comprises a 6-month
regimen, with a four-drug intensive phase and a two-drug continuation phase. Alternative …